日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細


公開

学術論文

Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1

MPS-Authors
/persons/resource/persons252185

LaMont,  Colin H.
Max Planck Research Group Statistical physics of evolving systems, Max Planck Institute for Dynamics and Self-Organization, Max Planck Society;

/persons/resource/persons246034

Otwinowski,  Jakub
Max Planck Research Group Statistical physics of evolving systems, Max Planck Institute for Dynamics and Self-Organization, Max Planck Society;

/persons/resource/persons221181

Nourmohammad,  Armita
Max Planck Research Group Statistical physics of evolving systems, Max Planck Institute for Dynamics and Self-Organization, Max Planck Society;

External Resource
There are no locators available
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
フルテキスト (公開)

elife-76004-v2.pdf
(出版社版), 4MB

付随資料 (公開)
There is no public supplementary material available
引用

LaMont, C. H., Otwinowski, J., Vanshylla, K., Gruell, H., Klein, F., & Nourmohammad, A. (2022). Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1. eLife, 11:. doi:10.7554/eLife.76004.


引用: https://hdl.handle.net/21.11116/0000-000C-BC9E-F
要旨
Infusion of broadly neutralizing antibodies (bNAbs) has shown promise as an alternative to anti-retroviral therapy against HIV. A key challenge is to suppress viral escape, which is more effectively achieved with a combination of bNAbs. Here, we propose a computational approach to predict the efficacy of a bNAb therapy based on the population genetics of HIV escape, which we parametrize using high-throughput HIV sequence data from bNAb-naive patients. By quantifying the mutational target size and the fitness cost of HIV-1 escape from bNAbs, we predict the distribution of rebound times in three clinical trials. We show that a cocktail of three bNAbs is necessary to effectively suppress viral escape, and predict the optimal composition of such bNAb cocktail. Our results offer a rational therapy design for HIV, and show how genetic data can be used to predict treatment outcomes and design new approaches to pathogenic control.